161 related articles for article (PubMed ID: 29168892)
1. Functional properties of dopamine transporter oligomers after copper linking.
Zhen J; Reith MEA
J Neurochem; 2018 Jan; 144(2):162-171. PubMed ID: 29168892
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor mechanisms in the S1 binding site of the dopamine transporter defined by multi-site molecular tethering of photoactive cocaine analogs.
Krout D; Pramod AB; Dahal RA; Tomlinson MJ; Sharma B; Foster JD; Zou MF; Boatang C; Newman AH; Lever JR; Vaughan RA; Henry LK
Biochem Pharmacol; 2017 Oct; 142():204-215. PubMed ID: 28734777
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities.
Zhen J; Antonio T; Cheng SY; Ali S; Jones KT; Reith ME
J Neurochem; 2015 Apr; 133(2):167-73. PubMed ID: 25580950
[TBL] [Abstract][Full Text] [Related]
4. Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells.
Chen N; Reith ME
J Neurochem; 2007 Apr; 101(2):377-88. PubMed ID: 17250655
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding.
Moritz AE; Foster JD; Gorentla BK; Mazei-Robison MS; Yang JW; Sitte HH; Blakely RD; Vaughan RA
J Biol Chem; 2013 Jan; 288(1):20-32. PubMed ID: 23161550
[TBL] [Abstract][Full Text] [Related]
6. The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain.
Lee FJ; Pristupa ZB; Ciliax BJ; Levey AI; Niznik HB
J Biol Chem; 1996 Aug; 271(34):20885-94. PubMed ID: 8702845
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation.
Gorentla BK; Vaughan RA
Neuropharmacology; 2005 Nov; 49(6):759-68. PubMed ID: 16181646
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter.
Pristupa ZB; McConkey F; Liu F; Man HY; Lee FJ; Wang YT; Niznik HB
Synapse; 1998 Sep; 30(1):79-87. PubMed ID: 9704884
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter phosphorylation site threonine 53 is stimulated by amphetamines and regulates dopamine transport, efflux, and cocaine analog binding.
Challasivakanaka S; Zhen J; Smith ME; Reith MEA; Foster JD; Vaughan RA
J Biol Chem; 2017 Nov; 292(46):19066-19075. PubMed ID: 28939767
[TBL] [Abstract][Full Text] [Related]
10. Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate-binding site.
Dahal RA; Pramod AB; Sharma B; Krout D; Foster JD; Cha JH; Cao J; Newman AH; Lever JR; Vaughan RA; Henry LK
J Biol Chem; 2014 Oct; 289(43):29712-27. PubMed ID: 25179220
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity.
Price DA; Sorkin A; Zahniser NR
Mol Pharmacol; 2009 Oct; 76(4):812-23. PubMed ID: 19628755
[TBL] [Abstract][Full Text] [Related]
12. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter.
Lee SH; Chang MY; Lee KH; Park BS; Lee YS; Chin HR; Lee YS
Mol Pharmacol; 2000 May; 57(5):883-9. PubMed ID: 10779370
[TBL] [Abstract][Full Text] [Related]
13. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
14. Labeling of dopamine transporter transmembrane domain 1 with the tropane ligand N-[4-(4-azido-3-[125I]iodophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane implicates proximity of cocaine and substrate active sites.
Parnas ML; Gaffaney JD; Zou MF; Lever JR; Newman AH; Vaughan RA
Mol Pharmacol; 2008 Apr; 73(4):1141-50. PubMed ID: 18216182
[TBL] [Abstract][Full Text] [Related]
15. Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs.
Eriksen J; Rasmussen SG; Rasmussen TN; Vaegter CB; Cha JH; Zou MF; Newman AH; Gether U
J Neurosci; 2009 May; 29(21):6794-808. PubMed ID: 19474307
[TBL] [Abstract][Full Text] [Related]
16. Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.
Dehnes Y; Shan J; Beuming T; Shi L; Weinstein H; Javitch JA
Neurochem Int; 2014 Jul; 73():4-15. PubMed ID: 24576496
[TBL] [Abstract][Full Text] [Related]
17. Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.
Rothman RB; Ananthan S; Partilla JS; Saini SK; Moukha-Chafiq O; Pathak V; Baumann MH
J Pharmacol Exp Ther; 2015 Jun; 353(3):529-38. PubMed ID: 25788711
[TBL] [Abstract][Full Text] [Related]
18. Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding.
Chen N; Rickey J; Berfield JL; Reith ME
J Biol Chem; 2004 Feb; 279(7):5508-19. PubMed ID: 14660644
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4-dichlorophenyl)tropanes at the dopamine transporter.
Zou MF; Kopajtic T; Katz JL; Newman AH
J Med Chem; 2003 Jul; 46(14):2908-16. PubMed ID: 12825932
[TBL] [Abstract][Full Text] [Related]
20. The functional domains of dopamine transporter for cocaine analog, CFT binding.
Lee SH; Chang MY; Jeon DJ; Oh DY; Son H; Lee CH; Lee YS; Lee YS
Exp Mol Med; 2002 Mar; 34(1):90-4. PubMed ID: 11989984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
